title: Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality?
abstract: Mechanistic studies suggest that angiotensin II receptor blockers (ARBs) may have pleiotropic effects on the cardiovascular system in hemodialysis patients. A new randomized trial by Peters et al. failed to show a benefit of irbesartan on biomarkers of arterial stiffness, left ventricular mass, and autonomic nerve function. Their findings suggest that, like in the general population and other disease states, in hemodialysis patients the type of antihypertensive drug is unlikely to be of major clinical relevance.
authors.affiliation: 1] Nephrology, Hypertension and Renal Transplantation Unit, Ospedali Riuniti, Reggio Calabria, Italy [2] CNR (National Research Council of Italy) Institute of Clinical Physiology (IFC), Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension Unit, Ospedali Riuniti, Reggio Calabria, Italy.
authors.forename: Carmine
authors.initials: C
authors.lastname: Zoccali
authors.affiliation: 1] Nephrology, Hypertension and Renal Transplantation Unit, Ospedali Riuniti, Reggio Calabria, Italy [2] CNR (National Research Council of Italy) Institute of Clinical Physiology (IFC), Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension Unit, Ospedali Riuniti, Reggio Calabria, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Mallamaci
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D005260:Female; D006352:Heart Ventricles / Q000473:pathology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D000077405:Irbesartan; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan